Voyager Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Voyager Therapeutics

24/02/2025 22:24

* Voyager Therapeutics Inc  VYGR.OQ   VYGR.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2024
    * The Lexington Massachusetts-based  company is expected to
report
a 81.6% decrease in revenue to $16.577 million from $90.06
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Voyager Therapeutics Inc
is
for a loss of 37 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 12 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Voyager
Therapeutics Inc is $16.00​, above​ its last closing price
of $4.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.40       -0.45      -0.16     Beat    64.7
 Jun. 30 2024  -0.41       -0.41      -0.18     Beat    56
 Mar. 31 2024  -0.43       -0.44      -0.20     Beat    54.5​
 Dec. 31 2023  -0.16       -0.29      1.25      Beat    533.2
 ​​Sep.        -0.57       -0.58      -0.59     Missed  -1.5
 30 2023                                                
 Jun. 30 2023  -0.57       -0.57      -0.51     Beat    10.3​
 Mar. 31 2023  1.00        0.77       2.94      Beat    281
 Dec. 31 2022  -0.54       -0.55      -0.61     Missed  -11.5
 This summary was machine generated February 24 at 22:24 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)